VBL Therapeutics
6 Jonathan Netanyahu Street
Or Yehuda
60376
Tel: 97-236-346450
Fax: 97-236-346449
Website: http://www.vblrx.com/
Email: businessdev@vbl.co.il
204 articles about VBL Therapeutics
-
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
5/15/2023
VBL Therapeutics, announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
-
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
3/14/2023
VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.
-
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
3/9/2023
VBL Therapeutics announced that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.
-
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
3/1/2023
Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, announced that it has acquired a manufacturing facility in Modi’in, Israel, and certain related assets from biotechnology company VBL Therapeutics.
-
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
2/23/2023
VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement.
-
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
2/16/2023
VBL Therapeutics, a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced that it has entered into an agreement to monetize its manufacturing facility in Modiin, Israel and certain related assets, for $7.1 million in cash.
-
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
VBL Therapeutics, a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
-
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
9/1/2022
VBL Therapeutics announced that VBL received a written notification from the Nasdaq Stock Market LLC on August 31, 2022, notifying VBL that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.
-
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
8/15/2022
VBL Therapeutics, a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
VBL Therapeutics Announces Workforce Reduction
8/2/2022
VBL Therapeutics, a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, announced an organizational streamlining designed to reduce operating expenses and preserve capital.
-
VBL's ofra-vec candidate was primarily evaluated on its ability to improve PFS and OS in study participants—and delivered disappointing results for both measures.
-
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
7/19/2022
VBL Therapeutics today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene obadenovec; VB-111) in platinum-resistant ovarian cancer.
-
VBL Therapeutics to Participate in the Jefferies Healthcare Conference - May 31, 2022
5/31/2022
VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.
-
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/17/2022
VBL Therapeutics announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.
-
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
5/10/2022
VBL Therapeutics announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open.
-
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May 2022
5/3/2022
VBL Therapeutics announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022.
-
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 28, 2022
4/28/2022
VBL Therapeutics announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective April 24, 2022 of a non-qualified stock option to purchase an aggregate of 75,000 ordinary shares of VBL as an inducement material to the hiring of a new employee, in accordance with Nasdaq Listing Rule 5635.
-
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
-
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
4/26/2022
VBL Therapeutics (Nasdaq: VBLT), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.
-
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
3/31/2022
VBL Therapeutics today announced that it will host a key opinion leader (KOL) luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY.